

AMENDMENTS TO THE CLAIMS

1. – 38. (Canceled)

39. (Currently Amended) A method for treatment of tumors, which comprises administering to a subject in need thereof a composition comprising

(a) an effective amount of an anti-inflammatory active substance, wherein the anti-inflammatory active substance is a Dexamethasone selected from the group consisting of Dexamethasone, an ester of Dexamethasone, and a salt of Dexamethasone; and

(b) ~~a tubulin polymerization inhibitory active substance having anti-tumor activity selected from the group consisting of~~ (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide ~~and or~~ a salt thereof.

40. (Previously Presented) The method according to Claim 39, wherein said subject in need thereof is a human.

41. (Currently Amended) The method according to Claim 39, wherein said effective amount of said ~~tubulin polymerization inhibitory active substance having anti-tumor activity~~ (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide or a salt thereof ranges from 0.1-10000mg per day.

42. (Previously Presented) The method according to Claim 39, wherein said effective amount of said anti-inflammatory active substance ranges from 0.1-10000mg per day.

43. – 49. (Canceled)

50. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered simultaneously.

51. (Previously Presented) The method according to Claim 39, wherein (a) and (b) are administered sequentially.

52. (Previously Presented) The method according to Claim 39, wherein (a) is Dexamethasone.

53. (Previously Presented) The method according to Claim 39, wherein (a) is an ester of Dexamethasone.

54. (Previously Presented) The method according to Claim 39, wherein (a) is a salt of Dexamethasone.

55. (Previously Presented) The method according to Claim 39, wherein (b) is (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.

56. (Previously Presented) The method according to Claim 39, wherein (b) is a salt of (Z)-N-[2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)vinyl]phenyl]-L-serinamide.